(Q37258968)

English

The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics

scientific article published on May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Michael K K Wong

1

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

publication date

1 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Current Oncology Reports

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

259-263

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma and interleukin-2: what are the endpoints?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18765157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11912-008-0039-2

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37258968&oldid=2200095854"